An adopted Nuclear Receptor for Cancer and Metabolic Diseases.
LRH-1 reduced expression or dysfunction have been associated with several metabolic disease including diabetes, NAFLD/NASH, and dyslipidaemia as well as inflammatory disorders such as pancreatitis. Increasing LRH-1 activity is a novel approach to ameliorate the life-threatening conditions of thousands of patients affected by those diseases.
We are currently working to optimise a promising chemical series of small molecule LRH-1 agonists. These compounds demonstrate an increase of co-activator binding to LRH-1 as well as modulating LRH-1 target genes in liver cells.